Aurinia Pharmaceuticals (AUPH) Misses Q4 EPS by 2c

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q4 EPS of ($0.17), $0.02 worse than the analyst estimate of ($0.15).

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• RBC Capital Reiterates Sector Perform Rating on ExxonMobil (XOM)
• Raymond James Reiterates Underperform Rating on Lennar (LEN)